PepGen Experiences Setback as Phase 1 Study of Myotonic Dystrophy Asset Delayed
☀️Trending News PEPGEN ($NASDAQ:PEPG): PepGen Inc. is an innovative biotechnology company specializing in the development of treatments for rare and [...]
PepGen Receives Approval from Health Canada to Begin Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy
Trending News ☀️ PEPGEN ($NASDAQ:PEPG): PepGen Inc. is a biotechnology company that specializes in the development of therapies for rare [...]
PepGen Publishes Slide Deck to Accompany Event Presentation.
Trending News 🌥️ PEPGEN ($NASDAQ:PEPG): PepGen Inc. (PEPG) is a biotechnology company that focuses on developing innovative treatments for cancer, [...]
PepGen’s Q3 GAAP EPS of -$0.79 beats estimates by $0.21. Company has $195.8 million in cash and cash equivalents as of September 30, 2022.
Trending News 🌥️ Pepgen Inc Stock Fair Value – PEPGEN ($NASDAQ:PEPG): PepGen Inc. is a pharmaceutical company that focuses on [...]
PepGen’s PGN-EDO51 Drug Shows Promise in Early Clinical Trial
Trending News ☀️ Pepgen Inc Intrinsic Value – PEPGEN ($NASDAQ:PEPG): PepGen’s lead product candidate, PGN-EDO51, is being developed to treat [...]
PepGen’s PGN-EDO51 Drug Shows Promise in Early Clinical Trial
Trending News ☀️ Pepgen Inc Stock Fair Value – PEPGEN ($NASDAQ:PEPG): PepGen’s lead product candidate, PGN-EDO51, is being developed to [...]
